Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

LUND, Sweden, July 1, 2026 /PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ Stockholm: HNSA) and SERB S.A. ("SERB") today announced required regulatory approvals have been obtained and that the previously announced exclusive licensing transaction

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Wed, 01 Jul 2026 09:15:00 -0400

SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase

StreetInsider.com News Articles

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA